Quirós, L. P., and R. Ugalde. “Analysis of the Budgetary Impact of Alemtuzumab As Second-Line Therapy, Compared to Natalizumab and Fingolimod, in Patients Previously Treated With Interferon Beta 1b, Diagnosed With Active Relapsing-Remitting Multiple Sclerosis, Treated in the Costa Rican Social Security Fund”. Global and Regional Health Technology Assessment, vol. 6, no. 1, Mar. 2019, doi:10.33393/grhta.2019.467.